Key Takeaways
- • Blackstone and TPG have completed a $17.2 billion acquisition of Hologic, a leading medical diagnostics and women's health technology company, closing on April 7, 2026, following initial announcement in October 2025.
- • Hologic shareholders received $76 per share in cash plus a contingent value right of up to $3 per share tied to revenue milestones, with the deal securing $12.25 billion in debt financing from major banks.
- • Abu Dhabi Investment Authority and GIC Private Limited co-invested alongside Blackstone and TPG, reflecting institutional appetite for healthcare technology assets in the private equity market.
- • The transaction cleared all regulatory hurdles, including shareholder approval (February 5, 2026), European Commission clearance (February 16, 2026), and Chinese regulatory sign-off, demonstrating strong cross-border institutional support.
- • Hologic will remain headquartered in Marlborough, Massachusetts and operate under its existing brand and name, signaling continuity of operations under private equity ownership.
Summary
Blackstone and TPG have successfully closed a $17.2 billion acquisition of Hologic, Inc., a prominent medical technology company specializing in women's health and diagnostic testing. The transaction, which closed on April 7, 2026, represents a significant expansion of both firms' healthcare portfolios and underscores the sustained appetite among leading alternative asset managers for medical technology investments.
The deal structure provided Hologic shareholders with $76 per share in cash alongside a contingent value right of up to $3 per share contingent upon meeting specified revenue milestones. The acquisition was funded with $12.25 billion in debt financing arranged by major financial institutions, reflecting strong confidence from the lending community in the target's financial profile and cash generation potential.
The transaction timeline began with the initial announcement on October 21, 2025, followed by shareholder approval on February 5, 2026. Regulatory clearance proceeded smoothly across major jurisdictions, with European Commission approval granted on February 16, 2026, and Chinese regulatory approval also secured ahead of closing. Abu Dhabi Investment Authority and GIC Private Limited participated as co-investors alongside the two lead sponsors, expanding the ownership syndicate beyond the primary acquirers.
Operationally, Hologic will maintain its headquarters in Marlborough, Massachusetts and continue operations under the Hologic brand and name, providing business continuity for customers, employees, and stakeholders. The acquisition signals private equity's sustained strategic interest in medical technology and diagnostics—sectors characterized by stable cash flows, recurring revenue models, and resilient demand drivers tied to essential healthcare needs.
The deal structure provided Hologic shareholders with $76 per share in cash alongside a contingent value right of up to $3 per share contingent upon meeting specified revenue milestones. The acquisition was funded with $12.25 billion in debt financing arranged by major financial institutions, reflecting strong confidence from the lending community in the target's financial profile and cash generation potential.
The transaction timeline began with the initial announcement on October 21, 2025, followed by shareholder approval on February 5, 2026. Regulatory clearance proceeded smoothly across major jurisdictions, with European Commission approval granted on February 16, 2026, and Chinese regulatory approval also secured ahead of closing. Abu Dhabi Investment Authority and GIC Private Limited participated as co-investors alongside the two lead sponsors, expanding the ownership syndicate beyond the primary acquirers.
Operationally, Hologic will maintain its headquarters in Marlborough, Massachusetts and continue operations under the Hologic brand and name, providing business continuity for customers, employees, and stakeholders. The acquisition signals private equity's sustained strategic interest in medical technology and diagnostics—sectors characterized by stable cash flows, recurring revenue models, and resilient demand drivers tied to essential healthcare needs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.